A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy

American Journal of Physiology - Endocrinology and Metabolism

Volumn 297, Issue 5, 2009, Pages

  Blümer, Regje M E ^a   Van Der Valk, Marc ^a   Ackermans, Mariette ^a   Endert, Erik ^a   Serlie, Mireille J ^a   Reiss, Peter ^a   Sauerwein, Hans P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Adipocytokines; Human immunodeficiency virus associated lipodystrophy; Insulin resistance

Indexed keywords

ADIPONECTIN; GLUCOSE; PLACEBO; ROSIGLITAZONE;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT DISTRIBUTION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; GLUCOSE METABOLISM; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID METABOLISM; LIPOLYSIS; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD;

ABSORPTIOMETRY, PHOTON; ADIPONECTIN; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; CALORIMETRY, INDIRECT; DOUBLE-BLIND METHOD; GLUCOSE; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPID METABOLISM; LIPOLYSIS; MALE; MIDDLE AGED; PPAR GAMMA; THIAZOLIDINEDIONES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 70350440110     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.90988.2008     Document Type: Article

References (40)

1. Ackermans MT, Ruiter AF, Endert E. Determination of glycerol concentrations and glycerol isotopic enrichments in human plasma by gas chromatography/mass spectrometry. Anal Biochem 258: 80-86, 1998. (Pubitemid 28163147)
2. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 11: 327-332, 2000.
3. Basu R, Pajvani UB, Rizza RA, Scherer PE. Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: differential regulation from nondiabetic subjects. Diabetes 56: 2174-2177, 2007. (Pubitemid 47195840)
4. Blumer RM, van Vonderen MG, Sutinen J, Hassink E, Ackermans M, van Agtmael MA, Yki-Jarvinen H, Danner SA, Reiss P, Sauerwein HP. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS 22: 227-236, 2008.
5. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 17, Suppl 1: S141-S148, 2003. (Pubitemid 36667790)
6. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, Wand H, Law M, Samaras K, Emery S, Cooper DA. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 363: 429-438, 2004. (Pubitemid 38210059)
7. Cavalcanti RB, Raboud J, Kain KC, Walmsley S. Rosiglitazone for HIV-1 lipoatrophy. Lancet 363: 1828-1829, 2004.
8. Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA, Laplante M, Nawrocki AR, Rajala MW, Parlow AF, Cheeseboro L, Ding YY, Russell RG, Lindemann D, Hartley A, Baker GR, Obici S, Deshaies Y, Ludgate M, Rossetti L, Scherer PE. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145: 367-383, 2004. (Pubitemid 38094532)
9. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 55: 628-634, 1983.
10. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 98: 2005-2010, 2001. (Pubitemid 32165613)
11. Gastaldelli A, Miyazaki Y, Mahankali A, Berria R, Pettiti M, Buzzigoli E, Ferrannini E, DeFronzo RA. The effect of pioglitazone on the liver: role of adiponectin. Diabetes Care 29: 2275-2281, 2006. (Pubitemid 44899865)
12. Gelato MC, Mynarcik DC, Quick JL, Steigbigel RT, Fuhrer J, Brathwaite CE, Brebbia JS, Wax MR, McNurlan MA. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. J Acquir Immune Defic Syndr 31: 163-170, 2002. (Pubitemid 35190570)
13. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med 140: 786-794, 2004. (Pubitemid 38623528)
14. Haider DG, Schindler K, Mittermayer F, Muller M, Nowotny P, Rieger A, Luger A, Ludvik B, Wolzt M. Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients. Clin Pharmacol Ther 81: 580-585, 2007. (Pubitemid 46452301)
15. Haugaard SB, Andersen O, Dela F, Holst JJ, Storgaard H, Fenger M, Iversen J, Madsbad S. Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic beta-cells. Eur J Endocrinol 152: 103-112, 2005. (Pubitemid 40185458)
16. Jones SP, Janneh O, Back DJ, Pirmohamed M. Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. Antivir Ther 10: 207-213, 2005. (Pubitemid 41151026)
17. Kovacs P, Stumvoll M. Fatty acids and insulin resistance in muscle and liver. Best Pract Res Clin Endocrinol Metab 19: 625-635, 2005. (Pubitemid 41819222)
18. Lagathu C, Kim M, Maachi M, Vigouroux C, Cervera P, Capeau J, Caron M, Bastard JP. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo. Biochimie 87: 65-71, 2005. (Pubitemid 40298767)
19. Lee GA, Rao MN, Grunfeld C. The effects of HIV protease inhibitors on carbohydrate and lipid metabolism. Curr HIV/AIDS Rep 2: 39-50, 2005.
20. Lindegaard B, Keller P, Bruunsgaard H, Gerstoft J, Pedersen BK. Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients. Clin Exp Immunol 135: 273-279, 2004. (Pubitemid 38177967)
21. Matsuda M, DeFronzo RA, Glass L, Consoli A, Giordano M, Bressler P, Delprato S. Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. Metabolism 51: 1111-1119, 2002.
22. Mulligan K, Yang Y, Wininger DA, Koletar SL, Parker RA, Alston- Smith BL, Schouten JT, Fielding RA, Basar MT, Grinspoon S. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS 21: 47-57, 2007. (Pubitemid 44912536)
23. Mynarcik DC, Combs T, McNurlan MA, Scherer PE, Komaroff E, Gelato MC. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J Acquir Immune Defic Syndr 31: 514-520, 2002. (Pubitemid 35448659)
24. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione- mediated improvement in insulin sensitivity. J Biol Chem 279: 12152-12162, 2004. (Pubitemid 38445780)
25. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection HIV Outpatient Study Investigators. N Engl J Med 338: 853-860, 1998.
26. Qurashi S, Mynarcik DC, McNurlan MA, Ahn H, Ferris R, Gelato MC. Importance of the high molecular weight isoform of adiponectin in improved insulin sensitivity with rosiglitazone treatment in HIV disease. Clin Sci (Lond) 115: 197-202, 2008.
27. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 55: 1537-1545, 2006. (Pubitemid 44324105)
28. Serlie MJ, Allick G, Groener JE, Ackermans MT, Heijligenberg R, Voermans BC, Aerts JM, Meijer AJ, Sauerwein HP. Chronic treatment with pioglitazone does not protect obese patients with diabetes mellitus type II from free fatty acid-induced insulin resistance. J Clin Endocrinol Metab 92: 166-171, 2007. (Pubitemid 46067526)
29. Shlay JC, Visnegarwala F, Bartsch G, Wang J, Peng G, El Sadr WM, Gibert C, Kotler D, Grunfeld C, Raghavan S. Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr 38: 147-155, 2005. (Pubitemid 40189321)
30. Sinha MK, Songer T, Xiao Q, Sloan JH, Wang J, Ji S, Alborn WE, Davis RA, Swarbrick MM, Stanhope KL, Wolfe BM, Havel PJ, Schraw T, Konrad RJ, Scherer PE, Mistry JS. Analytical validation and biological evaluation of a high molecular-weight adiponectin ELISA. Clin Chem 53: 2144-2151, 2007. (Pubitemid 350197298)
31. Sutinen J, Kannisto K, Korsheninnikova E, Fisher RM, Ehrenborg E, Nyman T, Virkamaki A, Funahashi T, Matsuzawa Y, Vidal H, Hamsten A, Yki-Jarvinen H. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metab 286: E941-E949, 2004. (Pubitemid 38668816)
32. Sutinen J, Korsheninnikova E, Funahashi T, Matsuzawa Y, Nyman T, Yki-Jarvinen H. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab 88: 1907-1910, 2003.
33. Sweeney LL, Brennan AM, Mantzoros CS. The role of adipokines in relation to HIV lipodystrophy. AIDS 21: 895-904, 2007.
34. van der Valk M, Allick G, Weverling GJ, Romijn JA, Ackermans MT, Lange JM, Eck-Smit BL, van Kuijk C, Endert E, Sauerwein HP, Reiss P. Markedly diminished lipolysis and partial restoration of glucose metabolism, without changes in fat distribution after extended discontinuation of protease inhibitors in severe lipodystrophic human immunodeficient virus-1-infected patients. J Clin Endocrinol Metab 89: 3554-3560, 2004. (Pubitemid 38951934)
35. van der Valk M, Bisschop PH, Romijn JA, Ackermans MT, Lange JM, Endert E, Reiss P, Sauerwein HP. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 15: 2093-2100, 2001. (Pubitemid 33101816)
36. van Wijk JP, de Koning EJ, Cabezas MC, op 't Roodt J, Joven J, Rabelink TJ, Hoepelman AI. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med 143: 337-346, 2005.
37. Wang Y, Lam KS, Yau MH, Xu A. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J 409: 623-633, 2008. (Pubitemid 351214189)
38. Wu X, Motoshima H, Mahadev K, Stalker TJ, Scalia R, Goldstein BJ. Involvement of AMP-activated protein kinase in glucose uptake stimulated by the globular domain of adiponectin in primary rat adipocytes. Diabetes 52: 1355-1363, 2003. (Pubitemid 36666188)
39. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8: 1288-1295, 2002. (Pubitemid 35373562)
40. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7: 941-946, 2001. (Pubitemid 32756432)